Saad Alobid1,#, Hussam Albassam1,#, Tebyan O. Mirgany2, Faris Almutairi1, Mohammed Mufadhe Alanazi1, Ahmed H. Bakheit2, Hanadi H. Asiri2, Eram Eltahir3, Gamaleldin I. Harisa3,*
Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2025.073371
- 23 March 2026
Abstract Objective: Glioblastoma (GB) therapy is challenged by tumor heterogeneity and multidrug resistance (MDR), highlighting the need for effective therapies. This study aimed to explore the combined anticancer effects of Sunitinib (SNB) and Fenofibrate (FEN) on U87 cells. Methods: U87 cells were exposed to SNB, FEN, or their combination for 24 h, followed by evaluations of cell viability, migration, and clonogenic survival using MTT, scratch, and colony formation assays. Intracellular reactive oxygen species (ROS) were quantified via the 2′, 7′-dichlorofluorescein assay, while mitochondrial membrane potential (MMP) was assessed using JC-1 red/green fluorescence. Molecular docking was performed to… More >
Graphic Abstract